The pharmaceutical industry’s commercial trade function is undergoing a fundamental transformation, driven by mounting policy pressures and the growing complexity of specialty therapies.
Regulatory frameworks including the 340B drug pricing programme and the Inflation Reduction Act have dramatically altered how manufacturers must approach product launches from the earliest planning stages.
Industry veterans Jon Hamrick, Rena Goins, and Bob Cochran gathered to examine why leaving trade teams out of early launch conversations has become an increasingly costly mistake.
Their discussion, released on November 10th, 2026, forms the first instalment of what promises to be a searching examination of how commercial trade strategy must evolve.
The central argument running through the conversation is direct: trade strategy can no longer be treated as a downstream function that engages only after key launch decisions have already been made.
The 340B programme, which governs drug pricing for eligible healthcare entities, creates complex reimbursement dynamics that trade teams must anticipate well before a product reaches the market.
Similarly, provisions within the Inflation Reduction Act have introduced new negotiation pressures and pricing considerations that ripple through every stage of a product’s commercial lifecycle.
Specialty therapies add yet another layer of difficulty, given their higher price points, limited patient populations, and the intricate distribution channels they typically require to reach patients effectively.
Hamrick, Goins, and Cochran collectively argue that the convergence of these forces means trade teams must have a seat at the table during the earliest phases of launch planning rather than being consulted after strategies are already set.
The conversation reflects a broader industry reckoning with how traditional launch models, built around simpler market environments, are increasingly ill-suited to the regulatory and commercial realities manufacturers face today.
For companies preparing specialty product launches, the message from these three experienced voices is clear: integrating trade expertise early is no longer optional but a commercial imperative.
The discussion arrives at a moment when pharmaceutical companies are reassessing the boundaries between market access, trade, and commercial functions as policy complexity continues to grow.